Dr. Lal PathLabs Yönetim

Yönetim kriter kontrolleri 2/4

Dr. Lal PathLabs' CEO'su Shankha Banerjee, May2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.027% doğrudan sahiptir ve bu hisselerin değeri ₹ 76.03M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.5 yıl ve 5.5 yıldır.

Anahtar bilgiler

Shankha Banerjee

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	0.03%
Yönetim ortalama görev süresi	4.5yrs
Yönetim Kurulu ortalama görev süresi	5.5yrs

Son yönetim güncellemeleri

Recent updates

CEO

Shankha Banerjee

less than a year

Görev süresi

Mr. Shankha Banerjee serves as Chief Executive Officer of Group & Associates Companies at Dr. Lal PathLabs Limited. He served as Chief Operating Officer at Dr. Lal PathLabs Limited since 2020. He had been...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Arvind Lal	Executive Chairman	29.7yrs	₹30.14m	32.93% ₹ 86.1b
Om Manchanda	MD & Director	4.5yrs	₹46.45m	1.04% ₹ 2.7b
Vandana Lal	Executive Director	no data	₹24.18m	19.3% ₹ 50.5b
Shankha Banerjee	Chief Executive Officer	less than a year	Veri yok	0.027% ₹ 69.8m
Ved Goel	Group CFO & CEO of International Business	6.2yrs	₹7.30m	0.014% ₹ 37.8m
Jai Meena	Chief Operating Officer	2.5yrs	Veri yok	Veri yok
Munender Soperna	Chief Information & Digital Officer	10.3yrs	Veri yok	0.025% ₹ 65.6m
Vinay Gujral	Company Secretary & Compliance Officer	1.5yrs	Veri yok	0.00066% ₹ 1.7m
Manoj Garg	Group Chief Human Resources Officer	10yrs	Veri yok	0.033% ₹ 85.3m

4.5yrs

Ortalama Görev Süresi

63.5yo

Ortalama Yaş

Deneyimli Yönetim: 539524 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Arvind Lal	Executive Chairman	29.7yrs	₹30.14m	32.93% ₹ 86.1b
Om Manchanda	MD & Director	13.7yrs	₹46.45m	1.04% ₹ 2.7b
Vandana Lal	Executive Director	29.7yrs	₹24.18m	19.3% ₹ 50.5b
Arun Duggal	Lead Independent Director	1.7yrs	₹3.85m	Veri yok
Rajit Mehta	Independent Director	1.3yrs	₹1.56m	Veri yok
Rahul Sharma	Non Executive Director	19.3yrs	₹2.65m	0.024% ₹ 62.8m
Rohit Bhasin	Independent Non-Executive Director	1.9yrs	₹2.60m	Veri yok
Somya Satsangi	Independent Director	5.7yrs	₹2.70m	Veri yok
Archana Erdmann	Non-Executive Director	5.4yrs	₹2.25m	1.85% ₹ 4.8b
Gurinder Singh Kalra	Independent Director	1.3yrs	₹1.56m	Veri yok

5.5yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 539524 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.5 yıldır).

Dr. Lal PathLabs Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Dr. Lal Pathlabs Limited Announces Stepping Down of Dr. Om Prakash Manchanda as Managing Director, Effective March 31, 2025

MD & Director recently sold ₹28m worth of stock

Non Executive Director recently sold ₹14m worth of stock

MD & Director recently sold ₹20m worth of stock

MD & Director recently sold ₹28m worth of stock

MD & Director recently sold ₹37m worth of stock

Recent updates

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Dr. Lal Pathlabs Limited Announces Stepping Down of Dr. Om Prakash Manchanda as Managing Director, Effective March 31, 2025

Dr. Lal PathLabs Limited to Report Q2, 2025 Results on Oct 23, 2024

MD & Director recently sold ₹28m worth of stock

Price target increased by 7.2% to ₹2,794

First quarter 2025 earnings: EPS exceeds analyst expectations

Dr. Lal PathLabs Limited Approves Interim Dividend for the Fiscal Year 2024-25

Dr. Lal PathLabs Limited to Report Q1, 2025 Results on Aug 07, 2024

Non Executive Director recently sold ₹14m worth of stock

MD & Director recently sold ₹20m worth of stock

MD & Director recently sold ₹28m worth of stock

MD & Director recently sold ₹37m worth of stock

Upcoming dividend of ₹6.00 per share

MD & Director recently sold ₹29m worth of stock

MD & Director recently sold ₹36m worth of stock

Dr. Lal PathLabs Limited, Annual General Meeting, Jun 29, 2024

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Dr. Lal PathLabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Dr. Lal PathLabs Limited to Report Q4, 2024 Results on May 10, 2024

Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024

MD & Director recently sold ₹33m worth of stock

MD & Director recently sold ₹23m worth of stock

MD & Director recently sold ₹43m worth of stock

Upcoming dividend of ₹12.00 per share at 0.7% yield

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24

Dr. Lal PathLabs Limited to Report Q3, 2024 Results on Feb 01, 2024

Chief Executive Officer recently sold ₹7.6m worth of stock

Chief Executive Officer recently sold ₹2.6m worth of stock

Non Executive Director recently sold ₹7.8m worth of stock

Price target increased by 8.0% to ₹2,353

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr. Lal PathLabs Limited to Report Q2, 2024 Results on Nov 02, 2023

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023

Dr. Lal PathLabs Limited Announces Change in Directorate

Dr. Lal PathLabs Limited Announces Change in Directorate

MD & Director recently sold ₹32m worth of stock

Upcoming dividend of ₹12.00 per share at 0.5% yield

Price target increased by 7.2% to ₹2,091

Dr. Lal PathLabs Limited, Annual General Meeting, Sep 12, 2023

Dr. Lal Pathlabs Limited Proposes Interim Dividend for the Financial Year 2023-24

First quarter 2024 earnings released: EPS: ₹9.95 (vs ₹6.97 in 1Q 2023)

MD & Director recently sold ₹41m worth of stock

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves Appointment of Vinay Gujral as Company Secretary

Full year 2023 earnings: EPS and revenues miss analyst expectations

MD & Director recently sold ₹14m worth of stock

MD & Director recently sold ₹48m worth of stock

MD & Director recently sold ₹41m worth of stock

Rajat Kalra Resigns as Company Secretary and Compliance Officer of Dr. Lal Pathlabs Limited, Effective on or Before May 04, 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited (NSEI:LALPATHLAB) agreed to acquire additional 10% stake in Aprl Pathlabs Private Limited for INR 7.5 million.

Dr. Lal PathLabs Limited to Report Q3, 2023 Results on Feb 02, 2023

Chief Executive Officer recently sold ₹3.6m worth of stock

MD & Director recently sold ₹48m worth of stock

MD & Director recently sold ₹61m worth of stock

MD & Director recently sold ₹57m worth of stock

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited to Report Q2, 2023 Results on Nov 08, 2022

MD & Director recently sold ₹33m worth of stock

Non Executive Director recently sold ₹2.5m worth of stock

MD & Director recently sold ₹117m worth of stock

Dr. Lal Pathlabs Limited Declares an Interim Dividend for the Financial Year 2022-23, Payable on or Before August 26, 2022

First quarter 2023 earnings: EPS misses analyst expectations

Dr. Lal PathLabs Limited to Report Q1, 2023 Results on Jul 28, 2022

Dr. Lal Pathlabs Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Non-Executive Director recently sold ₹164m worth of stock